Navigation Links
New Anal Cancer Therapy Fails to Improve Outcomes
Date:4/22/2008

Experimental use of cisplatin no better than standard treatment, researchers say

TUESDAY, April 22 (HealthDay News) -- Compared to the standard treatment regimen for anal canal cancer, the use of the chemotherapy drug cisplatin before other treatments didn't improve disease-free survival and resulted in a higher rate of colostomy procedures, says a U.S. study.

Currently, the preferred primary therapy for patients with anal canal cancer is chemoradiation (concurrent use of radiation and the anti-cancer drugs fluorouracil/mitomycin), which achieves a five-year survival rate of about 65 percent, according to background information in the study.

It's been suggested that reducing cancer in the primary tumor and in the lymph node or nodes prior to chemoradiation might improve disease-free survival. Pilot studies using cisplatin prior to chemoradiation showed promise.

In this new, randomized controlled trial, Dr. Jaffer A. Ajani, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues compared treatment with fluorouracil plus mitomycin and radiation therapy to treatment with fluorouracil plus cisplatin and radiation therapy.

The findings from 644 patients showed a five-year, disease-free survival rate of 60 percent in the mitomycin group and 54 percent in the cisplatin group. The five-year overall survival rate was 75 percent in the mitomycin group and 70 percent in the cisplatin group. There were more cancer-related deaths in the cisplatin group (54) than in the mitomycin group (28).

The five-year, local-regional cancer recurrence and distant metastasis rates were 25 percent and 15 percent, respectively, for the mitomycin group and 33 percent and 19 percent, respectively, for the cisplatin group. Severe blood toxicity was worse in the mitomycin group. The cisplatin group had a higher rate of colostomy (19 percent vs. 10 percent).

"The question remains how to further improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin," the study authors wrote. "Options to explore included targeted agents (e.g., results with concurrent cetuximab plus radiation for head/neck cancer), dose escalation with intensity-modulated radiation plus concurrent chemotherapy, and surgical excision of residual cancer after concurrent chemoradiation at an earlier interval, when sphincter preservation may still be feasible in select patients."

The study was published in this week's issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about anal cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover a mechanism that can send cells on the road to cancer
2. Factors in Cancer Death Rates Stay Stagnant
3. Cancer Death Rates Stay Stagnant
4. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
5. Phone counseling improves quality of life, immune systems of cervical cancer survivors
6. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
7. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. American Cancer Society report details cancer prevention efforts
10. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for ... , All through the year, Garden Media aims to provide material helpful to ... influencers and pitching client’s key messages to gain coveted media placements, Garden ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for eating ... of disordered eating, announced today that the 2017 Symposium set a new attendance record ... countries converged on the Green Valley Resort in Las Vegas. , “We are ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 Global ... industry including definitions, classifications, applications and industry chain structure. ... market including development history, competitive landscape analysis, and major ... ... spread across 105 pages providing 10 company profiles and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
Breaking Medicine Technology: